Results 91 to 100 of about 120,396 (306)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Influence of Prognostic Risk Indicators on Osseointegrated Dental Implant Failure: A Matched Case-Control Analysis

, 2012
Dental implant treatment is an important therapeutic modality with documented long-term success for replacement of missing teeth. However, dental implants can be susceptible to disease conditions or healing complications that may lead to implant loss ...
Rami Alissa, Richard J. Oliver
core   +1 more source

Staphylococcal response to daptomycin in implant-associated infections [PDF]

, 2011
The use of medical devices carries the risk of infection. Due to the development of multi-resistant bacteria, missing microcirculation, and biofilm embedded bacteria these implant-associated infections are difficult to treat.
John, Anne-Kathrin
core   +1 more source

Assessing the Impact of Dental Implant Length on Early Failure Rates: A Retrospective Analysis

Journal of Pharmacy and Bioallied Sciences
Introduction: The selection criteria of implant is very critical. Implant length determines the mechanics of osseointegration. Objective: To investigate the influence of dental implant length on early failure rates, osseointegration success, peri-implant
Bhuvaneshwari Karthikeyan, K Hanumantha Kumar, K. Sadananda, Inderjit Murugendrappa Gowdar, Shital J. Sonune, Doaa Abdelaziz A. Helal   +5 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Poorer survival after a primary implant during revision total knee arthroplasty [PDF]

, 2013
Revision total knee arthroplasty (rTKA) is a complex procedure. Depending on the degree of ligament and bone damage, either primary or revision implants are used.
Meijer, Marrigje F., Reininga, Inge H. F.; id_orcid, Meijer, M.F., Stevens, M., Boerboom, Alexander L., Stevens, Martin; id_orcid, Bulstra, Sjoerd K., Reininga, Inge H. F., Boerboom, A.L., Stevens, Martin, Reininga, I.H.F., Bulstra, S.K.   +11 more
core   +1 more source

Implant failure after ankle arthrodesis versus total ankle arthroplasty: a matched- cohort study

Journal of the Foot & Ankle
Objective: To compare the risk of implant failure between ankle arthrodesis and total ankle arthroplasty using propensity score matching and time-to-event analysis.
Cláudia Diniz Freitas, Natália Helena Tau, Deivid Ramos dos Santos, Eduardo Cezar Silva dos Santos   +3 more
doaj   +1 more source